Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apremilast PK and Safety in Pediatric Plaque Psoriasis
NCT02576678Phase 2Completed
- Sponsor
- Amgen
- Start
- Oct 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of apremilast in plaque psoriasis, sponsored by Amgen. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Maximum Observed Plasma Concentration at Day 14 and 6 more. Started Oct 2015; status: completed.
02
Drugs
apremilast
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT02576678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576678.